nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—RXRB—Vitamin D Metabolism—CYP27B1—multiple sclerosis	0.045	0.0863	CbGpPWpGaD
Tazarotene—RXRB—Vitamin D Metabolism—CYP24A1—multiple sclerosis	0.045	0.0863	CbGpPWpGaD
Tazarotene—Pain of skin—Cladribine—multiple sclerosis	0.0307	0.0677	CcSEcCtD
Tazarotene—Localised oedema—Cladribine—multiple sclerosis	0.0287	0.0632	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.0197	0.0377	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.0197	0.0377	CbGpPWpGaD
Tazarotene—Blood triglycerides increased—Fingolimod—multiple sclerosis	0.0195	0.043	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.0176	0.0338	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.0176	0.0338	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.0169	0.0324	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.0169	0.0324	CbGpPWpGaD
Tazarotene—RXRB—Vitamin D Metabolism—VDR—multiple sclerosis	0.0147	0.0282	CbGpPWpGaD
Tazarotene—Localized exfoliation—Triamcinolone—multiple sclerosis	0.0133	0.0294	CcSEcCtD
Tazarotene—Eczema—Fingolimod—multiple sclerosis	0.0103	0.0227	CcSEcCtD
Tazarotene—Leukoderma—Prednisolone—multiple sclerosis	0.00919	0.0202	CcSEcCtD
Tazarotene—Leukoderma—Triamcinolone—multiple sclerosis	0.00845	0.0186	CcSEcCtD
Tazarotene—Leukoderma—Methylprednisolone—multiple sclerosis	0.00843	0.0186	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—PGR—multiple sclerosis	0.00842	0.0161	CbGpPWpGaD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00797	0.0153	CbGpPWpGaD
Tazarotene—Leukoderma—Dexamethasone—multiple sclerosis	0.00767	0.0169	CcSEcCtD
Tazarotene—Leukoderma—Betamethasone—multiple sclerosis	0.00767	0.0169	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—PGR—multiple sclerosis	0.00756	0.0145	CbGpPWpGaD
Tazarotene—Inflammation—Cladribine—multiple sclerosis	0.00747	0.0165	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors—PGR—multiple sclerosis	0.00724	0.0139	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—PGR—multiple sclerosis	0.00724	0.0139	CbGpPWpGaD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00715	0.0137	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—VDR—multiple sclerosis	0.00711	0.0136	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00686	0.0131	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00686	0.0131	CbGpPWpGaD
Tazarotene—Leukoderma—Prednisone—multiple sclerosis	0.00668	0.0147	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00666	0.0128	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00643	0.0123	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—VDR—multiple sclerosis	0.00638	0.0122	CbGpPWpGaD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—VDR—multiple sclerosis	0.00612	0.0117	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—VDR—multiple sclerosis	0.00612	0.0117	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Triamcinolone—multiple sclerosis	0.00604	0.0133	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methylprednisolone—multiple sclerosis	0.00603	0.0133	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00597	0.0114	CbGpPWpGaD
Tazarotene—Swelling—Cladribine—multiple sclerosis	0.00596	0.0131	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors—VDR—multiple sclerosis	0.00589	0.0113	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00577	0.0111	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00572	0.011	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00572	0.011	CbGpPWpGaD
Tazarotene—Leukoderma—Methotrexate—multiple sclerosis	0.00558	0.0123	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00553	0.0106	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Betamethasone—multiple sclerosis	0.00548	0.0121	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Dexamethasone—multiple sclerosis	0.00548	0.0121	CcSEcCtD
Tazarotene—Blister—Prednisolone—multiple sclerosis	0.00542	0.0119	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—VDR—multiple sclerosis	0.00528	0.0101	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—VDR—multiple sclerosis	0.00506	0.0097	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—VDR—multiple sclerosis	0.00506	0.0097	CbGpPWpGaD
Tazarotene—Blister—Triamcinolone—multiple sclerosis	0.00498	0.011	CcSEcCtD
Tazarotene—Hypertriglyceridaemia—Prednisone—multiple sclerosis	0.00494	0.0109	CcSEcCtD
Tazarotene—Stinging—Prednisolone—multiple sclerosis	0.00482	0.0106	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.00465	0.00892	CbGpPWpGaD
Tazarotene—Acne—Prednisolone—multiple sclerosis	0.00464	0.0102	CcSEcCtD
Tazarotene—Blister—Dexamethasone—multiple sclerosis	0.00452	0.00996	CcSEcCtD
Tazarotene—Blister—Betamethasone—multiple sclerosis	0.00452	0.00996	CcSEcCtD
Tazarotene—Stinging—Triamcinolone—multiple sclerosis	0.00443	0.00977	CcSEcCtD
Tazarotene—Blood triglycerides increased—Prednisone—multiple sclerosis	0.00433	0.00955	CcSEcCtD
Tazarotene—Acne—Triamcinolone—multiple sclerosis	0.00427	0.00941	CcSEcCtD
Tazarotene—Acne—Methylprednisolone—multiple sclerosis	0.00426	0.00939	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.00417	0.008	CbGpPWpGaD
Tazarotene—Stinging—Betamethasone—multiple sclerosis	0.00402	0.00887	CcSEcCtD
Tazarotene—Stinging—Dexamethasone—multiple sclerosis	0.00402	0.00887	CcSEcCtD
Tazarotene—RARA—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.004	0.00767	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.004	0.00767	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Methotrexate—multiple sclerosis	0.00399	0.00879	CcSEcCtD
Tazarotene—Swelling—Mitoxantrone—multiple sclerosis	0.00392	0.00863	CcSEcCtD
Tazarotene—Acne—Dexamethasone—multiple sclerosis	0.00387	0.00854	CcSEcCtD
Tazarotene—Acne—Betamethasone—multiple sclerosis	0.00387	0.00854	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00381	0.00731	CbGpPWpGaD
Tazarotene—Inflammation—Methylprednisolone—multiple sclerosis	0.0037	0.00814	CcSEcCtD
Tazarotene—Haemoglobin—Cladribine—multiple sclerosis	0.00366	0.00806	CcSEcCtD
Tazarotene—Haemorrhage—Cladribine—multiple sclerosis	0.00364	0.00802	CcSEcCtD
Tazarotene—Oedema peripheral—Cladribine—multiple sclerosis	0.00358	0.0079	CcSEcCtD
Tazarotene—Dermatitis contact—Triamcinolone—multiple sclerosis	0.00355	0.00782	CcSEcCtD
Tazarotene—Skin exfoliation—Triamcinolone—multiple sclerosis	0.00343	0.00756	CcSEcCtD
Tazarotene—Skin exfoliation—Methylprednisolone—multiple sclerosis	0.00342	0.00754	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00342	0.00655	CbGpPWpGaD
Tazarotene—Burning sensation—Methotrexate—multiple sclerosis	0.00342	0.00752	CcSEcCtD
Tazarotene—Acne—Prednisone—multiple sclerosis	0.00337	0.00743	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00336	0.00644	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00328	0.00628	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00328	0.00628	CbGpPWpGaD
Tazarotene—Pruritus—Fingolimod—multiple sclerosis	0.00323	0.00711	CcSEcCtD
Tazarotene—Dermatitis contact—Betamethasone—multiple sclerosis	0.00322	0.0071	CcSEcCtD
Tazarotene—Dermatitis contact—Dexamethasone—multiple sclerosis	0.00322	0.0071	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00322	0.00618	CbGpPWpGaD
Tazarotene—Erythema—Cladribine—multiple sclerosis	0.00317	0.00698	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00316	0.00606	CbGpPWpGaD
Tazarotene—Skin exfoliation—Betamethasone—multiple sclerosis	0.00311	0.00686	CcSEcCtD
Tazarotene—Skin exfoliation—Dexamethasone—multiple sclerosis	0.00311	0.00686	CcSEcCtD
Tazarotene—Haemoglobin—Azathioprine—multiple sclerosis	0.00297	0.00655	CcSEcCtD
Tazarotene—Dermatitis bullous—Prednisolone—multiple sclerosis	0.00297	0.00654	CcSEcCtD
Tazarotene—Haemorrhage—Azathioprine—multiple sclerosis	0.00296	0.00652	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00295	0.00566	CbGpPWpGaD
Tazarotene—RARG—retina—multiple sclerosis	0.00292	0.119	CbGeAlD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00284	0.00544	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—MAPK1—multiple sclerosis	0.00277	0.0053	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Triamcinolone—multiple sclerosis	0.00273	0.00601	CcSEcCtD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00272	0.00521	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00272	0.00521	CbGpPWpGaD
Tazarotene—Skin exfoliation—Prednisone—multiple sclerosis	0.00271	0.00597	CcSEcCtD
Tazarotene—Discomfort—Cladribine—multiple sclerosis	0.00266	0.00587	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00265	0.00508	CbGpPWpGaD
Tazarotene—Skin discolouration—Methotrexate—multiple sclerosis	0.00263	0.00579	CcSEcCtD
Tazarotene—Dry skin—Prednisolone—multiple sclerosis	0.0026	0.00573	CcSEcCtD
Tazarotene—Oedema—Cladribine—multiple sclerosis	0.00258	0.00569	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00257	0.00492	CbGpPWpGaD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00257	0.00492	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00254	0.00487	CbGpPWpGaD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00254	0.00487	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00253	0.00486	CbGpPWpGaD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00253	0.00486	CbGpPWpGaD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—MAPK1—multiple sclerosis	0.00248	0.00475	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Dexamethasone—multiple sclerosis	0.00248	0.00546	CcSEcCtD
Tazarotene—Dermatitis bullous—Betamethasone—multiple sclerosis	0.00248	0.00546	CcSEcCtD
Tazarotene—Inflammation—Methotrexate—multiple sclerosis	0.00245	0.00539	CcSEcCtD
Tazarotene—Haemoglobin—Mitoxantrone—multiple sclerosis	0.0024	0.0053	CcSEcCtD
Tazarotene—Haemorrhage—Mitoxantrone—multiple sclerosis	0.00239	0.00527	CcSEcCtD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—MAPK1—multiple sclerosis	0.00238	0.00456	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—MAPK1—multiple sclerosis	0.00238	0.00456	CbGpPWpGaD
Tazarotene—Skin exfoliation—Methotrexate—multiple sclerosis	0.00227	0.00499	CcSEcCtD
Tazarotene—Pain—Cladribine—multiple sclerosis	0.00221	0.00487	CcSEcCtD
Tazarotene—Dry skin—Betamethasone—multiple sclerosis	0.00217	0.00478	CcSEcCtD
Tazarotene—Dry skin—Dexamethasone—multiple sclerosis	0.00217	0.00478	CcSEcCtD
Tazarotene—Discomfort—Azathioprine—multiple sclerosis	0.00217	0.00477	CcSEcCtD
Tazarotene—Erythema—Mitoxantrone—multiple sclerosis	0.00208	0.00459	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00208	0.00399	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00208	0.00399	CbGpPWpGaD
Tazarotene—RARG—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	0.00207	0.00397	CbGpPWpGaD
Tazarotene—Haemoglobin—Prednisolone—multiple sclerosis	0.00197	0.00434	CcSEcCtD
Tazarotene—Haemorrhage—Prednisolone—multiple sclerosis	0.00196	0.00432	CcSEcCtD
Tazarotene—Dry skin—Prednisone—multiple sclerosis	0.00189	0.00416	CcSEcCtD
Tazarotene—RARB—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	0.00186	0.00356	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.00184	0.00353	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—ZNF746—multiple sclerosis	0.00183	0.00352	CbGpPWpGaD
Tazarotene—Pruritus—Cladribine—multiple sclerosis	0.00183	0.00403	CcSEcCtD
Tazarotene—RARB—cerebellum—multiple sclerosis	0.00183	0.0746	CbGeAlD
Tazarotene—Haemoglobin—Triamcinolone—multiple sclerosis	0.00181	0.004	CcSEcCtD
Tazarotene—Haemoglobin—Methylprednisolone—multiple sclerosis	0.00181	0.00399	CcSEcCtD
Tazarotene—Haemorrhage—Triamcinolone—multiple sclerosis	0.0018	0.00398	CcSEcCtD
Tazarotene—Haemorrhage—Methylprednisolone—multiple sclerosis	0.0018	0.00397	CcSEcCtD
Tazarotene—RXRB—nervous system—multiple sclerosis	0.00178	0.0728	CbGeAlD
Tazarotene—RXRB—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	0.00178	0.00342	CbGpPWpGaD
Tazarotene—RARA—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	0.00178	0.00342	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.00177	0.00338	CbGpPWpGaD
Tazarotene—Discomfort—Mitoxantrone—multiple sclerosis	0.00175	0.00386	CcSEcCtD
Tazarotene—RXRB—central nervous system—multiple sclerosis	0.00172	0.0701	CbGeAlD
Tazarotene—Erythema—Prednisolone—multiple sclerosis	0.00171	0.00376	CcSEcCtD
Tazarotene—Oedema—Mitoxantrone—multiple sclerosis	0.0017	0.00374	CcSEcCtD
Tazarotene—RXRB—cerebellum—multiple sclerosis	0.00168	0.0685	CbGeAlD
Tazarotene—RARG—Gene Expression—PTBP1—multiple sclerosis	0.00168	0.00322	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—FAS—multiple sclerosis	0.00165	0.00316	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—ZNF746—multiple sclerosis	0.00165	0.00315	CbGpPWpGaD
Tazarotene—Haemoglobin—Dexamethasone—multiple sclerosis	0.00165	0.00363	CcSEcCtD
Tazarotene—Haemoglobin—Betamethasone—multiple sclerosis	0.00165	0.00363	CcSEcCtD
Tazarotene—Haemorrhage—Betamethasone—multiple sclerosis	0.00164	0.00361	CcSEcCtD
Tazarotene—Haemorrhage—Dexamethasone—multiple sclerosis	0.00164	0.00361	CcSEcCtD
Tazarotene—Rash—Cladribine—multiple sclerosis	0.00163	0.00359	CcSEcCtD
Tazarotene—Dermatitis—Cladribine—multiple sclerosis	0.00163	0.00359	CcSEcCtD
Tazarotene—RARG—nervous system—multiple sclerosis	0.00158	0.0646	CbGeAlD
Tazarotene—RXRB—Gene Expression—ZNF746—multiple sclerosis	0.00158	0.00302	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ZNF746—multiple sclerosis	0.00158	0.00302	CbGpPWpGaD
Tazarotene—Erythema—Triamcinolone—multiple sclerosis	0.00157	0.00346	CcSEcCtD
Tazarotene—Erythema—Methylprednisolone—multiple sclerosis	0.00157	0.00345	CcSEcCtD
Tazarotene—RARG—central nervous system—multiple sclerosis	0.00152	0.0622	CbGeAlD
Tazarotene—RARB—Gene Expression—PTBP1—multiple sclerosis	0.00151	0.00289	CbGpPWpGaD
Tazarotene—RARG—cerebellum—multiple sclerosis	0.00149	0.0608	CbGeAlD
Tazarotene—RARA—nervous system—multiple sclerosis	0.00149	0.0608	CbGeAlD
Tazarotene—RARB—brain—multiple sclerosis	0.00148	0.0606	CbGeAlD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.00148	0.00283	CbGpPWpGaD
Tazarotene—Pain—Mitoxantrone—multiple sclerosis	0.00145	0.0032	CcSEcCtD
Tazarotene—RXRB—Gene Expression—PTBP1—multiple sclerosis	0.00144	0.00277	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PTBP1—multiple sclerosis	0.00144	0.00277	CbGpPWpGaD
Tazarotene—Discomfort—Prednisolone—multiple sclerosis	0.00144	0.00317	CcSEcCtD
Tazarotene—RARA—central nervous system—multiple sclerosis	0.00143	0.0585	CbGeAlD
Tazarotene—Haemoglobin—Prednisone—multiple sclerosis	0.00143	0.00316	CcSEcCtD
Tazarotene—Haemorrhage—Prednisone—multiple sclerosis	0.00143	0.00314	CcSEcCtD
Tazarotene—Erythema—Betamethasone—multiple sclerosis	0.00143	0.00314	CcSEcCtD
Tazarotene—Erythema—Dexamethasone—multiple sclerosis	0.00143	0.00314	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.00142	0.00272	CbGpPWpGaD
Tazarotene—RARA—cerebellum—multiple sclerosis	0.0014	0.0572	CbGeAlD
Tazarotene—Oedema—Prednisolone—multiple sclerosis	0.00139	0.00307	CcSEcCtD
Tazarotene—RXRB—brain—multiple sclerosis	0.00136	0.0557	CbGeAlD
Tazarotene—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.00136	0.00299	CcSEcCtD
Tazarotene—Rash—Azathioprine—multiple sclerosis	0.00133	0.00292	CcSEcCtD
Tazarotene—Dermatitis—Azathioprine—multiple sclerosis	0.00132	0.00292	CcSEcCtD
Tazarotene—Discomfort—Triamcinolone—multiple sclerosis	0.00132	0.00291	CcSEcCtD
Tazarotene—Discomfort—Methylprednisolone—multiple sclerosis	0.00132	0.0029	CcSEcCtD
Tazarotene—Oedema—Triamcinolone—multiple sclerosis	0.00128	0.00282	CcSEcCtD
Tazarotene—RARG—Gene Expression—HNRNPA1—multiple sclerosis	0.00127	0.00244	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—U2AF2—multiple sclerosis	0.00127	0.00244	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.00127	0.00243	CbGpPWpGaD
Tazarotene—Erythema—Prednisone—multiple sclerosis	0.00124	0.00273	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.00121	0.00233	CbGpPWpGaD
Tazarotene—RARG—brain—multiple sclerosis	0.00121	0.0494	CbGeAlD
Tazarotene—Discomfort—Dexamethasone—multiple sclerosis	0.0012	0.00264	CcSEcCtD
Tazarotene—Discomfort—Betamethasone—multiple sclerosis	0.0012	0.00264	CcSEcCtD
Tazarotene—Haemoglobin—Methotrexate—multiple sclerosis	0.0012	0.00264	CcSEcCtD
Tazarotene—Pain—Prednisolone—multiple sclerosis	0.00119	0.00263	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—multiple sclerosis	0.00119	0.00263	CcSEcCtD
Tazarotene—Oedema—Dexamethasone—multiple sclerosis	0.00116	0.00256	CcSEcCtD
Tazarotene—Oedema—Betamethasone—multiple sclerosis	0.00116	0.00256	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—PGR—multiple sclerosis	0.00115	0.0022	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—HNRNPA1—multiple sclerosis	0.00114	0.00219	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—U2AF2—multiple sclerosis	0.00114	0.00219	CbGpPWpGaD
Tazarotene—RARA—brain—multiple sclerosis	0.00114	0.0465	CbGeAlD
Tazarotene—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.00111	0.00212	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.00111	0.00212	CbGpPWpGaD
Tazarotene—Pain—Triamcinolone—multiple sclerosis	0.0011	0.00242	CcSEcCtD
Tazarotene—RXRB—Gene Expression—U2AF2—multiple sclerosis	0.00109	0.0021	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—HNRNPA1—multiple sclerosis	0.00109	0.0021	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—HNRNPA1—multiple sclerosis	0.00109	0.0021	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—U2AF2—multiple sclerosis	0.00109	0.0021	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00109	0.00209	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00109	0.00209	CbGpPWpGaD
Tazarotene—Rash—Mitoxantrone—multiple sclerosis	0.00107	0.00236	CcSEcCtD
Tazarotene—Dermatitis—Mitoxantrone—multiple sclerosis	0.00107	0.00236	CcSEcCtD
Tazarotene—Discomfort—Prednisone—multiple sclerosis	0.00104	0.0023	CcSEcCtD
Tazarotene—Erythema—Methotrexate—multiple sclerosis	0.00104	0.00229	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—PGR—multiple sclerosis	0.00103	0.00198	CbGpPWpGaD
Tazarotene—Oedema—Prednisone—multiple sclerosis	0.00101	0.00223	CcSEcCtD
Tazarotene—RARG—Gene Expression—ZFP36L1—multiple sclerosis	0.00101	0.00193	CbGpPWpGaD
Tazarotene—Pain—Betamethasone—multiple sclerosis	0.000995	0.00219	CcSEcCtD
Tazarotene—Pain—Dexamethasone—multiple sclerosis	0.000995	0.00219	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—PGR—multiple sclerosis	0.000989	0.0019	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—PGR—multiple sclerosis	0.000989	0.0019	CbGpPWpGaD
Tazarotene—Pruritus—Triamcinolone—multiple sclerosis	0.000907	0.002	CcSEcCtD
Tazarotene—Pruritus—Methylprednisolone—multiple sclerosis	0.000905	0.00199	CcSEcCtD
Tazarotene—RARB—Gene Expression—ZFP36L1—multiple sclerosis	0.000902	0.00173	CbGpPWpGaD
Tazarotene—Rash—Prednisolone—multiple sclerosis	0.000879	0.00194	CcSEcCtD
Tazarotene—Dermatitis—Prednisolone—multiple sclerosis	0.000878	0.00193	CcSEcCtD
Tazarotene—Discomfort—Methotrexate—multiple sclerosis	0.000872	0.00192	CcSEcCtD
Tazarotene—RXRB—Gene Expression—ZFP36L1—multiple sclerosis	0.000864	0.00166	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—ZFP36L1—multiple sclerosis	0.000864	0.00166	CbGpPWpGaD
Tazarotene—Pruritus—Dexamethasone—multiple sclerosis	0.000823	0.00181	CcSEcCtD
Tazarotene—Pruritus—Betamethasone—multiple sclerosis	0.000823	0.00181	CcSEcCtD
Tazarotene—RARA—Adipogenesis—STAT3—multiple sclerosis	0.000809	0.00155	CbGpPWpGaD
Tazarotene—Rash—Triamcinolone—multiple sclerosis	0.000808	0.00178	CcSEcCtD
Tazarotene—Dermatitis—Triamcinolone—multiple sclerosis	0.000807	0.00178	CcSEcCtD
Tazarotene—Rash—Methylprednisolone—multiple sclerosis	0.000806	0.00178	CcSEcCtD
Tazarotene—Dermatitis—Methylprednisolone—multiple sclerosis	0.000806	0.00178	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—VDR—multiple sclerosis	0.000803	0.00154	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PABPC1—multiple sclerosis	0.00078	0.00149	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TGFB1—multiple sclerosis	0.00075	0.00144	CbGpPWpGaD
Tazarotene—Rash—Betamethasone—multiple sclerosis	0.000733	0.00162	CcSEcCtD
Tazarotene—Rash—Dexamethasone—multiple sclerosis	0.000733	0.00162	CcSEcCtD
Tazarotene—Dermatitis—Dexamethasone—multiple sclerosis	0.000733	0.00161	CcSEcCtD
Tazarotene—Dermatitis—Betamethasone—multiple sclerosis	0.000733	0.00161	CcSEcCtD
Tazarotene—Pain—Methotrexate—multiple sclerosis	0.000724	0.00159	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—VDR—multiple sclerosis	0.000721	0.00138	CbGpPWpGaD
Tazarotene—Pruritus—Prednisone—multiple sclerosis	0.000717	0.00158	CcSEcCtD
Tazarotene—RARG—Gene Expression—RPL5—multiple sclerosis	0.000703	0.00135	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—TNF—multiple sclerosis	0.000701	0.00134	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PABPC1—multiple sclerosis	0.000699	0.00134	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—VDR—multiple sclerosis	0.000691	0.00132	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—VDR—multiple sclerosis	0.000691	0.00132	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PABPC1—multiple sclerosis	0.00067	0.00129	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PABPC1—multiple sclerosis	0.00067	0.00129	CbGpPWpGaD
Tazarotene—Rash—Prednisone—multiple sclerosis	0.000639	0.00141	CcSEcCtD
Tazarotene—Dermatitis—Prednisone—multiple sclerosis	0.000638	0.00141	CcSEcCtD
Tazarotene—RARB—Gene Expression—RPL5—multiple sclerosis	0.000631	0.00121	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—RPL5—multiple sclerosis	0.000605	0.00116	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—RPL5—multiple sclerosis	0.000605	0.00116	CbGpPWpGaD
Tazarotene—Pruritus—Methotrexate—multiple sclerosis	0.000599	0.00132	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000577	0.00111	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000577	0.00111	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000575	0.0011	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—IL6—multiple sclerosis	0.000565	0.00108	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000564	0.00108	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—PGR—multiple sclerosis	0.000554	0.00106	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000553	0.00106	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000551	0.00106	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000541	0.00104	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000537	0.00103	CbGpPWpGaD
Tazarotene—Rash—Methotrexate—multiple sclerosis	0.000534	0.00118	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—multiple sclerosis	0.000533	0.00117	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000515	0.000987	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PGR—multiple sclerosis	0.000497	0.000952	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PGR—multiple sclerosis	0.000476	0.000913	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PGR—multiple sclerosis	0.000476	0.000913	CbGpPWpGaD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000468	0.000897	CbGpPWpGaD
Tazarotene—CYP2C8—brain—multiple sclerosis	0.000451	0.0184	CbGeAlD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000424	0.000814	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000424	0.000814	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—VDR—multiple sclerosis	0.000387	0.000742	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—VDR—multiple sclerosis	0.000347	0.000665	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—VDR—multiple sclerosis	0.000333	0.000638	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—VDR—multiple sclerosis	0.000333	0.000638	CbGpPWpGaD
Tazarotene—RARG—Generic Transcription Pathway—MYC—multiple sclerosis	0.000319	0.000612	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—MYC—multiple sclerosis	0.000286	0.000549	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—MYC—multiple sclerosis	0.000275	0.000526	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—MYC—multiple sclerosis	0.000275	0.000526	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—SRM—multiple sclerosis	0.000268	0.000514	CbGpPWpGaD
Tazarotene—CYP2C8—Biological oxidations—POMC—multiple sclerosis	0.000249	0.000477	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	0.000189	0.000362	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	0.000189	0.000362	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000185	0.000354	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—GPC5—multiple sclerosis	0.000173	0.000331	CbGpPWpGaD
Tazarotene—RARG—Gene Expression—MYC—multiple sclerosis	0.000154	0.000295	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—RRM1—multiple sclerosis	0.000143	0.000275	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—MYC—multiple sclerosis	0.000138	0.000264	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—MYC—multiple sclerosis	0.000132	0.000253	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—MYC—multiple sclerosis	0.000132	0.000253	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000111	0.000213	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.55e-05	0.000183	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.7e-05	0.000167	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—BCHE—multiple sclerosis	8.23e-05	0.000158	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—APOE—multiple sclerosis	4.95e-05	9.49e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—POMC—multiple sclerosis	4.25e-05	8.15e-05	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—ALB—multiple sclerosis	3.88e-05	7.43e-05	CbGpPWpGaD
